Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naïve patientsFootnote^*
* Meetings: These data were preliminarily presented at the 10th International Conference on HIV Treatment and Prevention Adherence, Miami, 28–30 June 2015.

Vagish HemmigeDivision of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA;Harris Health System, Houston, TX, USA

Charlene A. FlashDivision of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA;Harris Health System, Houston, TX, USA

http://orcid.org/0000-0002-3280-2134

Josephinel CarterTexas Southern University School of Health Sciences, Houston, TX, USA

Thomas P. GiordanoDivision of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA;Harris Health System, Houston, TX, USA;Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, TX, USACorrespondence[email protected]

Teddy ZeraiHarris Health System, Houston, TX, USA

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Julie Priest, Rachel H. Bhak, Maral Dersarkissian, Alan Oglesby, Colin Kunzweiler, Ellie Fuqua, Suna Park, Mei Sheng Duh & Cindy Garris. (2021) Retrospective analysis of adherence to HIV treatment and healthcare utilization in a commercially insured population. Journal of Medical Economics 24:1, pages 1204-1211.
Read now

Amedeo Capetti & Giuliano Rizzardini. (2019) Choosing appropriate pharmacotherapy for drug-resistant HIV. Expert Opinion on Pharmacotherapy 20:6, pages 667-678.
Read now

Filippo Lagi, Seble Tekle Kiros, Irene Campolmi, Susanna Giachè, Pier Giorgio Rogasi, Marcello Mazzetti, Filippo Bartalesi, Michele Trotta, Patrizia Nizzoli, Alessandro Bartoloni & Gaetana Sterrantino. (2018) Continuum of care among HIV-1 positive patients in a single center in Italy (2007–2017). Patient Preference and Adherence 12, pages 2545-2551.
Read now

Nicola Squillace, Giorgio Bozzi, Elisa Colella, Andrea Gori & Alessandra Bandera. (2018) Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. Drug Design, Development and Therapy 12, pages 3635-3643.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naïve patientsFootnote^*
* Meetings: These data were preliminarily presented at the 10th International Conference on HIV Treatment and Prevention Adherence, Miami, 28–30 June 2015.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naïve patientsFootnote** Meetings: These data were preliminarily presented at the 10th International Conference on HIV Treatment and Prevention Adherence, Miami, 28–30 June 2015.

Citations (4)

Read on this site (4)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naïve patientsFootnote^*
* Meetings: These data were preliminarily presented at the 10th International Conference on HIV Treatment and Prevention Adherence, Miami, 28–30 June 2015.